705 related articles for article (PubMed ID: 17077358)
1. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
Lu C; Kamat AA; Lin YG; Merritt WM; Landen CN; Kim TJ; Spannuth W; Arumugam T; Han LY; Jennings NB; Logsdon C; Jaffe RB; Coleman RL; Sood AK
Clin Cancer Res; 2007 Jul; 13(14):4209-17. PubMed ID: 17634550
[TBL] [Abstract][Full Text] [Related]
4. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
[TBL] [Abstract][Full Text] [Related]
5. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
7. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
10. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
11. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
12. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
13. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
[TBL] [Abstract][Full Text] [Related]
15. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
17. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
Gray MJ; Van Buren G; Dallas NA; Xia L; Wang X; Yang AD; Somcio RJ; Lin YG; Lim S; Fan F; Mangala LS; Arumugam T; Logsdon CD; Lopez-Berestein G; Sood AK; Ellis LM
J Natl Cancer Inst; 2008 Jan; 100(2):109-20. PubMed ID: 18182619
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
20. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
